Domain Specific Monoclonal Anti-Factor Viii Antibodies Generated by Inclusion Body-Renatured Factor Viii Peptides
Resource
THROMBOSIS RESEARCH v.101 n.5 pp.405-415
Journal
THROMBOSIS RESEARCH
Journal Volume
v.101
Journal Issue
n.5
Pages
405-415
Date Issued
2001
Date
2001
Author(s)
HUANG, CHIN-CHIN
LI, LI-TZU
SHEN, MING-CHING
CHEN, JEN-YANG
LIN, SHU-WHA
Abstract
Production of monoclonal anti-factor VIII (FVIII) antibodies was hampered by the availability of FVIII proteins devoid of albumin and the von Willebrand factor ( vWF). We showed a successful way to generate domain specific anti-FVIII antibodies by using a series of Escherichia coli expressed FVIII fusion peptides. A total of eight fusion peptides were synthesized to cover almost the entire coding region of FVIII. All except one of the fusion peptides were insoluble and became aggregated as inclusion bodies. Purification and refolding of the peptides were accomplished by solublizing them with denaturants and dialyzing them in appropriate buffers, this being followed by chromatography of the refolded fractions on a metal-ion chelating column. These purified FVIII fusion peptides were used individually or as a pool to immunize mice and generate antibodies. Three monoclonal antibodies, D2, E6 and B12, were obtained. D 2 recognizes a region (residues 1680-1703) of the light chain of FVIII, E6 recognizes a fragment (residues 744-1021) in the heavy chain, and B12, the A1 domain (residues 89-326). Both D2 and B12 inhibited >80% FVIII function. The affinities (k(A)) of the antibodies for FVIII were 1.62x10(7 ) M(-1) for D2 and 2.2x10(8) M(-1) for E6. Although B12 is inhibitory, it did not show a strong binding affinity with FVIII. The specificity of D2 and E6 for FVIII was demonstrated by immunoprecipitation of the FVIII protein in full-length recombinant FVIII(rFVIII) supplemented FVIII- deficient plasma, but not in FVIII-deficient plasma alone. An enzyme- linked immunosorbant assay (ELISA) using D2 or E6 was designed to detect plasma FVIII. The system may be useful in monitoring FVIII in cultured supernatants and in mouse models for gene therapy experiments.
Subjects
factor VII
monoclonal antibody
recombinant protein
COAGULATION-FACTOR-VIII
VON-WILLEBRAND-FACTOR